At a glance
- Originator Alcon
- Class Eye disorder therapies
- Mechanism of Action Glutathione peroxidase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cataracts
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon eye care devices business
- 19 Jan 1998 No-Development-Reported for Cataracts in USA (Unknown route)
- 26 Oct 1994 Preclinical development for Cataracts in USA (Unknown route)